<!DOCTYPE html>
<html lang="en-gb">
<head>
  
  <meta charset="utf-8" />
  <meta content="IE=edge,chrome=1" name="X-UA-Compatible" />
  <meta content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport" />
  
  <!-- meta tags -->
  <meta content="NICE" name="DC.Publisher" />
  <meta content="All content on this site is NICE copyright unless otherwise stated. You can download material for private research, study or in-house use only. Do not distribute or publish any material from this site without first obtaining NICE's permission. Where Crown copyright applies, see the Office of Public Sector Information (formerly HMSO) website for information." name="DC.Rights.Copyright" />
  <meta content="eng" name="DC.Language" scheme="DCTERMS.ISO639-2T" />
  <meta content="Health, well-being and care" name="DC.Subject" scheme="eGMS.IPSV" />
  <meta content="Double-A" name="eGMS.accessibility" scheme="eGMS.WCAG10" />
  <meta content="2014-08-05" name="DC.Issued" scheme="DCTERMS.W3CDTF" />
  <meta content="2014-08-05" name="DC.Modified" scheme="DCTERMS.W3CDTF" />
  <meta content="CorporatePage" name="DC.Type" scheme="NICE.Publication.Types" />
  
  <meta content="BNF: British National Formulary - NICE" name="DC.Title" />
  
  <title>RIBAVIRIN | Drug | BNF content published by NICE</title>
  <meta name="description" content="Indications, dose, contra-indications, side-effects, interactions, cautions, warnings and other safety information for RIBAVIRIN."/>
  <meta name="author" content="NICE - The National Institute for Health and Care Excellence" />

  	<link rel="alternate" type="application/json" href="/drug/ribavirin.json" title="RDF/JSON version of this document"/>
  	<link rel="alternate" type="text/turtle" href="/drug/ribavirin.ttl" title="Turtle version of this document"/>
  <!--[if lt IE 9]>
  <script src="//cdn.nice.org.uk/V3.1/Scripts/html5shiv/html5shiv.js"></script>
  <![endif]-->
  
  <!-- Le styles -->
  <link href="//fonts.googleapis.com/css?family=Lato:300normal,300italic,400normal,400italic,700normal,700italic" rel="stylesheet"/>
  <link href="//cdn.nice.org.uk/V3.1/Content/NICE.bootstrap.css" rel="stylesheet">
  <link rel="stylesheet" href="//maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css">
  
  <!--[if IE 7]>
  <link href="//cdn.nice.org.uk/V3.1/Content/NICE.glyphs-ie7.css" rel="stylesheet"/>
  <![endif]-->
  
  <meta content="#f6f6f6" name="msapplication-TileColor" />
  <meta content="//cdn.nice.org.uk/V3.1/Content/nice/favicon-144.png" name="msapplication-TileImage" />
  <link rel="shortcut icon" href="//cdn.nice.org.uk/V3.1/Content/nice/favicon.ico" />
  <link rel="apple-touch-icon-precomposed" href="//cdn.nice.org.uk/V3.1/Content/nice/favicon-152.png">
  
  <link href="/styles/style.css" rel="stylesheet" type="text/css" />
  <link href="/styles/bnf.css" rel="stylesheet" type="text/css" />
</head>
<body id="ribavirin" class="drug" data-publication="bnf" data-buildnumber="1.0.119-Live" data-release="live">
  
  
  <!-- Google Tag Manager -->
  <div id='gtmscript'></div>
  <noscript>
    <iframe src="//www.googletagmanager.com/ns.html?id=GTM-WF3WHX"
      height="0" width="0" style="display:none;visibility:hidden"></iframe>
  </noscript>
  <script>
    (function (w, d, s, l, i) {
      w[l] = w[l] || []; w[l].push({
        'gtm.start': new Date().getTime(), event: 'gtm.js'
      }); var f = d.getElementsByTagName(s)[0],
              j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
                '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
    })(window, document, 'script', 'dataLayer', 'GTM-WF3WHX');
  </script>
  <!-- End Google Tag Manager -->
  <div id="global-nav-header"></div>  <div class="container topic-container">
    
    <ul class="breadcrumb">
      <li><a href="../">Home</a> <span class="divider icon-nice-chevron-right"></span></li>
      <li><a href="./">Drugs</a> <span class="divider icon-nice-chevron-right"></span></li>
      <li class="active"><span>RIBAVIRIN</span></li>
    </ul>
  </div>
  
	<div class="container sticky-notice">
			<div id="site-distinction" class="bnf">
				<p>You are viewing BNF. If you require BNF for Children, use <a href="https://bnfc.nice.org.uk">BNFC.</a></p>
			</div>	</div>

  <div class="layout search-container hidden">
    <div id="search-results">
    </div>
  </div>
  <div class="layout">
    <h1 id=""><span>RIBAVIRIN</span></h1>
  </div>


  <div class="layout layout-secondary-wide topic-container">

    <div class="content content-primary">
      <nav class="nav-toggle">
        <ul class="index unstyled nav-subtopics">
          <li>
            <a class="btn btn-transparent">
              <i class="pull-right icon-chevron-down"></i>
              <span>Show all parts of this monograph</span>
            </a>
          </li>
        </ul>
      </nav>

      <nav class="monograph-navigation">
        <ul class="index unstyled nav-subtopics grid2">
            <li class="active"><a href="#indicationsAndDoses" class="scroll-to-href">Indications and dose</a></li>
            <li><a href="#unlicensedUse" class="scroll-to-href">Unlicensed use</a></li>
            <li><a href="#contraIndications" class="scroll-to-href">Contra-indications</a></li>
            <li><a href="#cautions" class="scroll-to-href">Cautions</a></li>
          <li><a href="#interactions" class="scroll-to-href">Interactions</a></li>
            <li><a href="#sideEffects" class="scroll-to-href">Side-effects</a></li>
            <li><a href="#conceptionAndContraception" class="scroll-to-href">Conception and contraception</a></li>
            <li><a href="#pregnancy" class="scroll-to-href">Pregnancy</a></li>
            <li><a href="#breastfeeding" class="scroll-to-href">Breast feeding</a></li>
            <li><a href="#renalImpairment" class="scroll-to-href">Renal impairment</a></li>
            <li><a href="#monitoringRequirements" class="scroll-to-href">Monitoring requirements</a></li>
            <li><a href="#prescribingAndDispensingInformations" class="scroll-to-href">Prescribing and dispensing information</a></li>
            <li><a href="#nationalFunding" class="scroll-to-href">National funding/access decisions</a></li>
            <li><a href="#lessSuitableForPrescribings" class="scroll-to-href">Less suitable for prescribing</a></li>
            <li><a href="#medicinalForms" class="scroll-to-href">Medicinal forms</a></li>
        </ul>
      </nav>

      <div id="monograph-content" class="">
      
        <section class="scroll-target" id="indicationsAndDoses">
          <h2>Indications and dose</h2>
      
      
          <h3>For <span>RIBAVIRIN</span></h3>
          <div class="prescribingInformation">
          <section class="indicationsAndDose">
            <section class="indicationAndDoseGroup">
              <h4 class="indications">
                <span class="indication"><span class="indication">Bronchiolitis</span></span><br/>
              </h4>
          
              <div class="dosage-group">
                <p class="specificity"><span class="routesOfAdministration">By inhalation of aerosol, or by inhalation of nebulised solution</span></p>
          
                <ul class="doses unstyled">
                  <li class="dose child">
                    <strong class="patientGroupList">For <span class="patientGroup">
                        <span>Child 1&#8211;23 months</span>
                    </span></strong><br/>
                    <p>Inhale a solution containing 20&#8239;mg/mL for 12&#8211;18 hours for at least 3 days, maximum of 7 days, to be administered via small particle aerosol generator.</p>
                  </li>
                </ul>
              </div>
            </section>
            <section class="indicationAndDoseGroup">
              <h4 class="indications">
                <span class="indication"><span class="indication">Life-threatening RSV, parainfluenza virus, and adenovirus infection in immunocompromised children (administered on expert advice)</span></span><br/>
              </h4>
          
              <div class="dosage-group">
                <p class="specificity"><span class="routesOfAdministration">By intravenous infusion</span></p>
          
                <ul class="doses unstyled">
                  <li class="dose child">
                    <strong class="patientGroupList">For <span class="patientGroup">
                        <span>Child</span>
                    </span></strong><br/>
                    <p>33&#8239;mg/kg for 1 dose, to be administered over 15 minutes, then 16&#8239;mg/kg every 6&#8239;hours for 4 days, then 8&#8239;mg/kg every 8&#8239;hours for 3 days.</p>
                  </li>
                </ul>
              </div>
            </section>
          </section>
          </div>
      
            <h3>For <span>Rebetol<sup class="tm">&#174;</sup> capsules</span></h3>
            <div id="rebetol-capsules_indicationsAndDoses">
              <p><a href="/clinical-medicinal-product-information/rebetol-capsules.html#indicationsAndDoses" data-action="load" data-target="#rebetol-capsules_indicationsAndDoses" data-filter="#indicationsAndDoses .prescribingInformation">See <span>Rebetol<sup class="tm">&#174;</sup> capsules</span></a></p>
            </div>
            <h3>For <span>Rebetol<sup class="tm">&#174;</sup> oral solution</span></h3>
            <div id="rebetol-oral-solution_indicationsAndDoses">
              <p><a href="/clinical-medicinal-product-information/rebetol-oral-solution.html#indicationsAndDoses" data-action="load" data-target="#rebetol-oral-solution_indicationsAndDoses" data-filter="#indicationsAndDoses .prescribingInformation">See <span>Rebetol<sup class="tm">&#174;</sup> oral solution</span></a></p>
            </div>
            <h3>For <span>Copegus<sup class="tm">&#174;</sup> tablets</span></h3>
            <div id="copegus-tablets_indicationsAndDoses">
              <p><a href="/clinical-medicinal-product-information/copegus-tablets.html#indicationsAndDoses" data-action="load" data-target="#copegus-tablets_indicationsAndDoses" data-filter="#indicationsAndDoses .prescribingInformation">See <span>Copegus<sup class="tm">&#174;</sup> tablets</span></a></p>
            </div>
        </section>
      
        <section class="scroll-target" id="unlicensedUse">
          <h2>Unlicensed use</h2>
      
      
          <div class="prescribingInformation">
          <section class="unlicencedUse">
              <section class="advice UnlicencedUse">
                <p class="specificity"><strong><span class="specificity">When used by <span class="route">inhalation</span> in children</span></strong></p>
                <div>
                              
                              <p>Inhalation licensed for use in children (age range not specified by manufacturer).</p>
                            </div>
              </section>
              <section class="advice UnlicencedUse">
                <p class="specificity"><strong><span class="specificity">With <span class="route">intravenous</span> use in children</span></strong></p>
                <div>
                              
                              <p>Intravenous preparation not licensed.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
      
        <section class="scroll-target" id="contraIndications">
          <h2>Contra-indications</h2>
      
      
          <div class="prescribingInformation">
          <section class="specificContraIndications">
            <div class="contraIndicationWithRoutes">
                <section class="advice ContraindicationsGroup,ContraindicationWithRoutes">
                  <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use</span></strong></p>
                  <p>
                  <span class="contraindication">consult product literature for specific contra-indications when ribavirin used in combination with other medicinal products</span>; <span class="contraindication">haemoglobinopathies</span>; <span class="contraindication">severe cardiac disease</span> (in adults); <span class="contraindication">severe, uncontrolled cardiac disease in children with chronic hepatitis C</span> (in children); <span class="contraindication">unstable or uncontrolled cardiac disease in previous 6 months</span> (in adults)</p>
                </section>
            </div>
          </section>
          </div>
      
        </section>
      
        <section class="scroll-target" id="cautions">
          <h2>Cautions</h2>
      
      
          <div class="prescribingInformation">
          <section class="specificCautions">
            <section class="cautionsWithRoutes">
                <section class="advice CautionsGroup,CautionsWithRoutes">
                  <p class="specificity"><strong><span class="specificity">When used by <span class="route">inhalation</span></span></strong></p>
                  <p>
                                    <span class="caution">maintain standard supportive respiratory and fluid management therapy</span>
                                  </p>
                </section>
                <section class="advice CautionsGroup,CautionsWithRoutes">
                  <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use</span></strong></p>
                  <p>
                  <span class="caution">anaemia (haemoglobin concentration should be monitored during the treatment and corrective action taken)</span> (in adults); <span class="caution">cardiac disease (assessment including ECG recommended before and during treatment&#8212;discontinue if deterioration)</span>; <span class="caution">consult product literature for specific cautions when ribavirin used in combination with other medicinal products</span>; <span class="caution">gout</span> (in adults); <span class="caution">haemolysis (haemoglobin concentration should be monitored during the treatment and corrective action taken)</span> (in adults); <span class="caution">patients with a transplant&#8212;risk of rejection</span>; <span class="caution">risk of growth retardation in children, the reversibility of which is uncertain&#8212;if possible, consider starting treatment after pubertal growth spurt</span> (in children); <span class="caution">severe dental disorders</span> (in adults); <span class="caution">severe ocular disorders</span> (in adults); <span class="caution">severe periodontal disorders</span> (in adults); <span class="caution">severe psychiatric effects</span> (in adults)</p>
                </section>
            </section>
          </section>
          </div>
      
        </section>
      
        <section class="scroll-target" id="interactions">
          <h2>Interactions</h2>
      
      
      
          <div class="interactants">
            <h4>Individual interactants:</h4>
            <ul>
              <li><a href="/interaction/ribavirin-2.html" class="interactant"><span> Ribavirin </span></a></li>
            </ul>
          </div>
      
        </section>
      
        <section class="scroll-target" id="sideEffects">
          <h2>Side-effects</h2>
      
      
          <div class="prescribingInformation">
          <section class="generalSideEffects">
            <div class="commonOrVeryCommon">
              <h4>Common or very common</h4>
                <section class="advice SideEffectsGroup,GeneralSideEffects,SideEffectGroup">
                  <p class="sideEffects">
                  <span class="sideEffect">Alopecia</span>; <span class="sideEffect">anaemia</span>; <span class="sideEffect">anxiety</span>; <span class="sideEffect">appetite decreased</span>; <span class="sideEffect">arrhythmias</span>; <span class="sideEffect">arthralgia</span>; <span class="sideEffect">arthritis</span>; <span class="sideEffect">asthenia</span>; <span class="sideEffect">behaviour abnormal</span>; <span class="sideEffect">chest pain</span>; <span class="sideEffect">chills</span>; <span class="sideEffect">concentration impaired</span>; <span class="sideEffect">constipation</span>; <span class="sideEffect">cough</span>; <span class="sideEffect">depression</span>; <span class="sideEffect">diarrhoea</span>; <span class="sideEffect">dizziness</span>; <span class="sideEffect">drowsiness</span>; <span class="sideEffect">dry mouth</span>; <span class="sideEffect">dysphagia</span>; <span class="sideEffect">dyspnoea</span>; <span class="sideEffect">ear pain</span>; <span class="sideEffect">eye disorders</span>; <span class="sideEffect">eye inflammation</span>; <span class="sideEffect">eye pain</span>; <span class="sideEffect">fever</span>; <span class="sideEffect">gastrointestinal discomfort</span>; <span class="sideEffect">gastrointestinal disorders</span>; <span class="sideEffect">haemorrhage</span>; <span class="sideEffect">headaches</span>; <span class="sideEffect">hyperthyroidism</span>; <span class="sideEffect">hypotension</span>; <span class="sideEffect">hypothyroidism</span>; <span class="sideEffect">increased risk of infection</span>; <span class="sideEffect">influenza like illness</span>; <span class="sideEffect">lymphadenopathy</span>; <span class="sideEffect">malaise</span>; <span class="sideEffect">memory loss</span>; <span class="sideEffect">mood altered</span>; <span class="sideEffect">muscle complaints</span>; <span class="sideEffect">muscle weakness</span>; <span class="sideEffect">nasal congestion</span>; <span class="sideEffect">nausea</span>; <span class="sideEffect">neutropenia</span>; <span class="sideEffect">oral disorders</span>; <span class="sideEffect">pain</span>; <span class="sideEffect">palpitations</span>; <span class="sideEffect">peripheral oedema</span>; <span class="sideEffect">photosensitivity reaction</span>; <span class="sideEffect">respiratory disorders</span>; <span class="sideEffect">sensation abnormal</span>; <span class="sideEffect">sexual dysfunction</span>; <span class="sideEffect">skin reactions</span>; <span class="sideEffect">sleep disorders</span>; <span class="sideEffect">sweat changes</span>; <span class="sideEffect">syncope</span>; <span class="sideEffect">taste altered</span>; <span class="sideEffect">thirst</span>; <span class="sideEffect">throat pain</span>; <span class="sideEffect">thrombocytopenia</span>; <span class="sideEffect">tinnitus</span>; <span class="sideEffect">tremor</span>; <span class="sideEffect">vasodilation</span>; <span class="sideEffect">vertigo</span>; <span class="sideEffect">vision disorders</span>; <span class="sideEffect">vomiting</span>; <span class="sideEffect">weight decreased</span></p>
                </section>
            </div>
            <div class="uncommon">
              <h4>Uncommon</h4>
                <section class="advice SideEffectsGroup,GeneralSideEffects,SideEffectGroup">
                  <p class="sideEffects">
                  <span class="sideEffect">Dehydration</span>; <span class="sideEffect">diabetes mellitus</span>; <span class="sideEffect">hallucination</span>; <span class="sideEffect">hearing loss</span>; <span class="sideEffect">hepatic disorders</span>; <span class="sideEffect">hypertension</span>; <span class="sideEffect">nerve disorders</span>; <span class="sideEffect">sarcoidosis</span>; <span class="sideEffect">suicidal tendencies</span>; <span class="sideEffect">thyroiditis</span></p>
                </section>
            </div>
            <div class="rareOrVeryRare">
              <h4>Rare or very rare</h4>
                <section class="advice SideEffectsGroup,GeneralSideEffects,SideEffectGroup">
                  <p class="sideEffects">
                  <span class="sideEffect">Angina pectoris</span>; <span class="sideEffect">angioedema</span>; <span class="sideEffect">bone marrow disorders</span>; <span class="sideEffect">cardiac inflammation</span>; <span class="sideEffect">cerebral ischaemia</span>; <span class="sideEffect">cholangitis</span>; <span class="sideEffect">coma</span>; <span class="sideEffect">congestive heart failure</span>; <span class="sideEffect">facial paralysis</span>; <span class="sideEffect">hepatic failure (<span class="sideEffectAction">discontinue</span>)</span>; <span class="sideEffect">hypersensitivity</span>; <span class="sideEffect">intracranial haemorrhage</span>; <span class="sideEffect">myocardial infarction</span>; <span class="sideEffect">myopathy</span>; <span class="sideEffect">pancreatitis</span>; <span class="sideEffect">psychotic disorder</span>; <span class="sideEffect">pulmonary embolism</span>; <span class="sideEffect">retinopathy</span>; <span class="sideEffect">seizure</span>; <span class="sideEffect">severe cutaneous adverse reactions (SCARs)</span>; <span class="sideEffect">systemic lupus erythematosus (SLE)</span>; <span class="sideEffect">vasculitis</span></p>
                </section>
            </div>
            <div class="notKnown">
              <h4>Frequency not known</h4>
                <section class="advice SideEffectsGroup,GeneralSideEffects,SideEffectGroup">
                  <p class="sideEffects">
                  <span class="sideEffect">Haemolytic anaemia</span>; <span class="sideEffect">homicidal ideation</span>; <span class="sideEffect">nephrotic syndrome</span>; <span class="sideEffect">pure red cell aplasia</span>; <span class="sideEffect">renal failure</span>; <span class="sideEffect">solid organ transplant rejection</span>; <span class="sideEffect">tongue discolouration</span>; <span class="sideEffect">ulcerative colitis</span></p>
                </section>
            </div>
          </section>
          <div class="sideEffectAdvice">
            <h3>Side-effects, further information</h3>
              <section class="advice SideEffectAdvice">
                <div>
                              <p>Side effects listed are reported when oral ribavirin is used in combination with peginterferon alfa or interferon alfa, consult product literature for details.</p>
                            </div>
              </section>
          </div>
          </div>
      
        </section>
      
      
        <section class="scroll-target" id="conceptionAndContraception">
          <h2>Conception and contraception</h2>
      
      
          <div class="prescribingInformation">
          <section class="conceptionAndContraception">
              <section class="advice ConceptionAndContraception">
                <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use</span></strong></p>
                <div>
                              
                              <p>Exclude pregnancy before treatment in females of childbearing age.</p>
                              <p>Effective contraception essential during treatment and for 4 months after treatment in females and for 7 months after treatment in males of childbearing age.</p>
                              <p>Routine monthly pregnancy tests recommended.</p>
                              <p>Condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen).</p>
                            </div>
              </section>
              <section class="advice ConceptionAndContraception">
                <p class="specificity"><strong><span class="specificity">When used by <span class="route">inhalation</span></span></strong></p>
                <div>
                              
                              <p>Women planning pregnancy should avoid exposure to aerosol.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
        <section class="scroll-target" id="pregnancy">
          <h2>Pregnancy</h2>
      
      
          <div class="prescribingInformation">
          <section class="generalInformation">
              <section class="advice GeneralInformation">
                <div>
                              <p>Avoid; teratogenicity in <em>animal</em> studies.</p>
                            </div>
              </section>
              <section class="advice GeneralInformation">
                <p class="specificity"><strong><span class="specificity">When used by <span class="route">inhalation</span></span></strong></p>
                <div>
                              
                              <p>Pregnant women should avoid exposure to aerosol.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
        <section class="scroll-target" id="breastfeeding">
          <h2>Breast feeding</h2>
      
      
          <div class="prescribingInformation">
          <section class="generalInformation">
            
              <section class="advice GeneralInformation">
                <div>
                              <p>Avoid&#8212;no information available.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
      
        <section class="scroll-target" id="renalImpairment">
          <h2>Renal impairment</h2>
      
      
          <div class="prescribingInformation">
          <section class="generalInformation">
              <section class="advice GeneralInformation">
                <div>
                              <p>Plasma-ribavirin concentration increased.</p>
                            </div>
              </section>
              <section class="advice GeneralInformation">
                <p class="specificity"><strong><span class="specificity">In adults</span></strong></p>
                <div>
                              
                              <p>Manufacturer advises avoid oral ribavirin unless essential if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;monitor haemoglobin concentration closely.</p>
                            </div>
              </section>
              <section class="advice GeneralInformation">
                <p class="specificity"><strong><span class="specificity">In children</span></strong></p>
                <div>
                              
                              <p>Manufacturer advises avoid oral ribavirin if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;monitor haemoglobin concentration closely.</p>
                              <p>Manufacturer advises use intravenous preparation with caution if estimated glomerular filtration rate less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
                            </div>
              </section>
          </section>
          
          </div>
      
        </section>
      
      
        <section class="scroll-target" id="monitoringRequirements">
          <h2>Monitoring requirements</h2>
      
      
          <div class="prescribingInformation">
          <section class="monitoringOfPatientParameters">
            <h3>Monitoring of patient parameters</h3>
              <section class="advice MonitoringOfPatientParameters,MonitoringRequirement">
                <p class="specificity"><strong><span class="specificity">When used by <span class="route">inhalation</span></span></strong></p>
                <div>
                              
                              <p>Monitor electrolytes closely.</p>
                              <p>Monitor equipment for precipitation.</p>
                            </div>
              </section>
              <section class="advice MonitoringOfPatientParameters,MonitoringRequirement">
                <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use in children</span></strong></p>
                <div>
                              
                              <p>Determine full blood count, platelets, electrolytes, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically&#8212;adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).</p>
                            </div>
              </section>
              <section class="advice MonitoringOfPatientParameters,MonitoringRequirement">
                <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use in adults</span></strong></p>
                <div>
                              
                              <p>Determine full blood count, platelets, electrolytes, glucose, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically&#8212;adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).</p>
                            </div>
              </section>
              <section class="advice MonitoringOfPatientParameters,MonitoringRequirement">
                <p class="specificity"><strong><span class="specificity">With <span class="route">systemic</span> use in children</span></strong></p>
                <div>
                              
                              <p>Test thyroid function before treatment and then every 3 months.</p>
                            </div>
              </section>
              <section class="advice MonitoringOfPatientParameters,MonitoringRequirement">
                <p class="specificity"><strong><span class="specificity">With <span class="route">oral</span> use in children</span></strong></p>
                <div>
                              
                              <p>Eye examination recommended before treatment.</p>
                              <p>Eye examination also recommended during treatment if pre-existing ophthalmological disorder or if decrease in vision reported&#8212;discontinue treatment if ophthalmological disorder deteriorates or if new ophthalmological disorder develops.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
      
      
      
        <section class="scroll-target" id="prescribingAndDispensingInformations">
          <h2>Prescribing and dispensing information</h2>
      
      
          <div class="prescribingInformation">
          <section class="prescribingAndDispensingInformation">
              <section class="advice PrescribingAndDispensingInformation">
                <div>
                              <p>Flavours of oral liquid formulations may include bubble-gum.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
      
      
      
        <section class="scroll-target" id="nationalFunding">
          <h2>National funding/access decisions</h2>
      
      
          <div class="prescribingInformation">
          <section class="niceDecisions">
            <h3>NICE decisions</h3>
            <section class="niceDecision">
              <h5 class="fundingIdentifier"><a href="http://www.nice.org.uk/TA200">NICE TA200</a></h5>
              <section class="advice FundingDecision,NiceDecisions">
                <h4>Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)</h4>
                <p class="specificity"><strong><span class="specificity">In adults</span></strong></p>
                <div class="niceDecision">
                                <p class="fundingIdentifier">NICE TA200</p>
                                <div>
                                  
                                  
                                  <p>The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (&#8216;watchful waiting&#8217;).</p>
                                </div>
                                <a href="http://www.nice.org.uk/TA200">www.nice.org.uk/TA200</a>
                              </div>
              </section>
            </section>
            <section class="niceDecision">
              <h5 class="fundingIdentifier"><a href="http://www.nice.org.uk/TA200">NICE TA200</a></h5>
              <section class="advice FundingDecision,NiceDecisions">
                <h4>Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)</h4>
                <p class="specificity"><strong><span class="specificity">In adults</span></strong></p>
                <div class="niceDecision">
                                <p class="fundingIdentifier">NICE TA200</p>
                                <div>
                                  
                                  
                                  <p>The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years: . </p>
                                  <ul>
                                    <li>not previously treated with interferon alfa or peginterferon alfa;</li>
                                    <li>treated previously with interferon alfa alone or in combination with ribavirin;</li>
                                    <li>whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;</li>
                                    <li>co-infected with HIV.</li>
                                  </ul>
                                  <p>Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.</p>
                                </div>
                                <a href="http://www.nice.org.uk/TA200">www.nice.org.uk/TA200</a>
                              </div>
              </section>
            </section>
            <section class="niceDecision">
              <h5 class="fundingIdentifier"><a href="http://www.nice.org.uk/TA300">NICE TA300</a></h5>
              <section class="advice FundingDecision,NiceDecisions">
                <h4>Peginterferon alfa and ribavirin for chronic hepatitis C (November 2013)</h4>
                <p class="specificity"><strong><span class="specificity">In children</span></strong></p>
                <div class="niceDecision">
                                <p class="fundingIdentifier">NICE TA300</p>
                                <div>
                                  
                                  
                                  <p>Peginterferon alfa in combination with ribavirin is recommended (within the marketing authorisation) as an option for treating chronic hepatitis C in children.</p>
                                </div>
                                <a href="http://www.nice.org.uk/TA300">www.nice.org.uk/TA300</a>
                              </div>
              </section>
            </section>
          </section>
          </div>
      
        </section>
      
        <section class="scroll-target" id="lessSuitableForPrescribings">
          <h2>Less suitable for prescribing</h2>
      
      
          <div class="prescribingInformation">
          <section class="lessSuitableForPrescribing">
              <section class="advice LessSuitableForPrescribing">
                <div>
                              <p>Ribavirin inhalation is less suitable for prescribing.</p>
                            </div>
              </section>
          </section>
          </div>
      
        </section>
      
      
        <section class="scroll-target" id="medicinalForms">
          <h2>Medicinal forms</h2>
      
          <section class="licensingVariationStatement">
            <p>There can be variation in the licensing of different medicines containing the same drug.</p>
          </section>
      
      
          <section class="medicinalForms">
            <p><a href="../medicinal-forms/ribavirin.html"><span>Tablet</span>,  <span>Capsule</span>,  <span>Oral solution</span>,  <span>Solution for injection</span> </a></p>
          </section>
        </section>
      </div>

      
      <div class="back-to-top-container">
        <a class="btn btn-default back-to-top">
        	<span class="hidden-xs">Back to top</span>
        	<span class="icon-chevron-up" style="padding: 0px 4px;"></span>
      	</a>
      </div>    </div>

    <div class="content content-secondary">

        <section class="related-links scroll-target related-treatment-summary" id="related-treatment-summary">
          <h4>Related Treatment Summaries</h4>
          <ul class="">
            <li>
              <a href="../treatment-summary/hepatitis.html" class="related-link"><span>Hepatitis</span></a>
            </li>
            <li>
              <a href="../treatment-summary/respiratory-syncytial-virus.html" class="related-link"><span>Respiratory syncytial virus</span></a>
            </li>
          </ul>
        </section>

        <section class="classifications scroll-target primary-classifications" id="primary-classifications">
          <div id="primary">
            <p>Other drugs classified as <a href="/drug-classification/primary/ribavirin.html" data-target="#primary" data-action="load" class="classification primary-classification">nucleoside analogues</a></p>
          </div>
        </section>

      

    </div>
  </div>

  
  <div id="global-nav-footer"></div>
  <script src="https://cdn.nice.org.uk/V3.1/Scripts/jquery/jquery-1.10.2.min.js"></script>
  
  
   
  <!-- Bootstrap  -->
  <script src="https://cdn.nice.org.uk/V3.1/Scripts/twitter.bootstrap.min.js"></script>
  <script src="https://cdn.nice.org.uk/V3.1/Scripts/NICE.bootstrap.min.js"></script>
  <script src="https://cdn.nice.org.uk/V3.1/Scripts/nice/NICE.EventTracking.js"></script>
  
  <script src="/scripts/remoteload.js"></script>
  <script src="/scripts/NICE.scrollspy.js"></script>
  <script src="/scripts/NICE.asyoutype.js"></script>
  <script src="/scripts/stickyfill.min.js"></script>
  <script src="/scripts/NICE.bnf.js"></script>
    <script>
  	    (function( $ ) {
  	      $(function() {
  	        var $backToTop = $( '#backToTop' );
  	        var $win = $( window );
  	        var opt = { min: 500, fadeSpeed: 100, scrollSpeed: 300 };
  	  
  	        $( document.body ).on('click', '#backToTop', function( ev ) {
  	          ev.preventDefault();
  	  
  	          $( "html, body" ).animate({ scrollTop: 0 }, opt.scrollSpeed );
  	        });
  	  
  	        $win.on('scroll', function() {
  	          $backToTop[ 'fade' + ( $win.scrollTop() >= opt.min ? 'In' : 'Out' ) ]( opt.fadeSpeed );
  	        });
  	      });
  	    })( jQuery );
  	  </script>
  	  	<script> 
  				var queryMatch = window.location.hash.match("q=([^&]+)");
  				var searchPlaceHolder = "Search BNFâ¦";
  				var global_nav_config = {
  				service: "bnf",
  				header: {
  					skipLinkId: "content-start",
  					cookie: true,
  					auth: {
  						environment: "live" == "live" ? "live" : "beta",
  						provider: "niceAccounts"
  					},
  					search: {
  						url: "/search?q=",
  						query: queryMatch ? decodeURIComponent(queryMatch[1]) : "",
  						autocomplete: "/typeahead?ajax=ajax",
  						placeholder: searchPlaceHolder,
  						onSearching: function(e) {
  								window.location.href = "#Search?q=" + encodeURIComponent(e.query);
  						}
  					},
  					onRendered: "globalNavRendered"
  				}
  	  	};
  	  </script>
  	  
  			<!--[if lt IE 9]>
  					<script src="//cdn.nice.org.uk/global-nav/global-nav.ie8.min.js"></script>
  			<![endif]-->
  			<script src="//cdn.nice.org.uk/global-nav/global-nav.min.js"></script>
  	
  	  
  
  
  
  <!-- Test for touch device -->
  <script type="text/javascript">
    $('body').addClass('ontouchstart' in document.documentElement ? 'touch-screen-device' : 'non-touch-screen-device');
  </script>
  
  <!-- TODO: What is this doing? -->
  <script type="text/javascript">
    $(document).ajaxSend(function (event, jqxhr, settings) { settings.url = settings.url + (~settings.url.indexOf("?") ? "&" : "?")+ "ajax=ajax"; });
  </script></body>
</html>
